Stock Events

Becton Dickinson 

$246.2
431
+$2.58+1.06% Friday 21:00

Statistics

Day High
246.6
Day Low
242.9
52W High
285.17
52W Low
226.09
Volume
992,660
Avg. Volume
1,606,740
Mkt Cap
71.13B
P/E Ratio
58.62
Dividend Yield
1.54%
Dividend
3.8

Upcoming

Dividends

1.54%Dividend Yield
Dec 23
$0.95
Sep 23
$0.91
Jun 23
$0.91
Mar 23
$0.91
Dec 22
$0.91

Earnings

2MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
2.4
2.74
3.09
3.43
Expected EPS
2.97
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BDX. It's not an investment recommendation.

Analyst Ratings

285$Average Price Target
The highest estimate is $305.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Show more...
CEO
Thomas Polen
Employees
75000
Country
US
ISIN
US0758871091
WKN
000857675

Listings